{"component": "clause", "props": {"groups": [{"samples": [{"hash": "f7lKat6vhI8", "uri": "/contracts/f7lKat6vhI8#development-activities", "label": "Hope Vi Revitalization Grant Agreement", "score": 24.3552360535, "published": true}, {"hash": "ccPk1YmsbYh", "uri": "/contracts/ccPk1YmsbYh#development-activities", "label": "Grant Agreement", "score": 22.1704311371, "published": true}, {"hash": "gwUO6apZDy7", "uri": "/contracts/gwUO6apZDy7#development-activities", "label": "Hope Vi Revitalization Grant Agreement", "score": 19.0, "published": true}], "size": 10, "snippet_links": [{"key": "development-activity", "type": "clause", "offset": [56, 76]}, {"key": "revitalization-plan", "type": "definition", "offset": [87, 106]}, {"key": "site-development", "type": "clause", "offset": [146, 162]}, {"key": "grantee-must", "type": "clause", "offset": [169, 181]}, {"key": "approval-of", "type": "definition", "offset": [193, 204]}, {"key": "development-proposal", "type": "definition", "offset": [207, 227]}, {"key": "cfr-part", "type": "clause", "offset": [247, 255]}, {"key": "from-time-to-time", "type": "clause", "offset": [309, 326]}, {"key": "standard-development", "type": "clause", "offset": [329, 349]}, {"key": "subpart-f", "type": "clause", "offset": [533, 542]}, {"key": "mixed-finance-development", "type": "clause", "offset": [614, 639]}, {"key": "construction-of", "type": "clause", "offset": [664, 679]}, {"key": "community-facilities", "type": "definition", "offset": [680, 700]}, {"key": "delivery-of", "type": "clause", "offset": [738, 749]}, {"key": "services-for", "type": "clause", "offset": [775, 787]}, {"key": "the-development", "type": "clause", "offset": [801, 816]}, {"key": "replacement-housing", "type": "definition", "offset": [843, 862]}, {"key": "comply-with", "type": "definition", "offset": [881, 892]}, {"key": "information-required", "type": "clause", "offset": [976, 996]}], "snippet": "(1) For any standard (non-mixed finance) public housing development activity under the Revitalization Plan (whether on-site reconstruction or off-site development), the Grantee must obtain HUD approval of a development proposal submitted under 24 CFR part 941 (or successor part), as this part may be amended from time to time (\"Standard Development Proposal\").\n(2) For mixed-finance housing development under the Revitalization Plan, the Grantee must obtain HUD approval of a mixed finance proposal submitted under 24 CFR part 941, subpart F (or successor part and subpart), as may be amended from time to time (\u201cMixed Finance Development Proposal\").\n(3) For new construction of community facilities primarily intended to facilitate the delivery of community and supportive services for residents of the Development and residents of off-site replacement housing, the Grantee must comply with 24 CFR part 941 (or successor part) as this part may be amended from time to time. Information required for this activity must be included in either a Standard or Mixed Finance Development Proposal.", "hash": "d4929b08bdc0cfa9d65479e97f8099b0", "id": 4}, {"samples": [{"hash": "hpocfi8s7s3", "uri": "/contracts/hpocfi8s7s3#development-activities", "label": "License and Development Agreement (Hana Biosciences Inc)", "score": 18.0, "published": true}, {"hash": "fA8VpISIcJ8", "uri": "/contracts/fA8VpISIcJ8#development-activities", "label": "License and Development Agreement (Hana Biosciences Inc)", "score": 18.0, "published": true}, {"hash": "3GoqkgJU0nj", "uri": "/contracts/3GoqkgJU0nj#development-activities", "label": "License and Development Agreement (Hana Biosciences Inc)", "score": 18.0, "published": true}], "size": 8, "snippet_links": [{"key": "the-non", "type": "clause", "offset": [105, 112]}, {"key": "license-fee", "type": "definition", "offset": [124, 135]}, {"key": "equity-transaction", "type": "definition", "offset": [138, 156]}, {"key": "section-44", "type": "clause", "offset": [170, 181]}], "snippet": "NovaDel shall not be required to commence any Development Activities until Licensee has executed 100% of the non-refundable License Fee & Equity transaction described in Section 4.4.", "hash": "3198f24db521519ac7406ad84d2bb9a3", "id": 5}, {"samples": [{"hash": "dX6BiuAi6Ku", "uri": "/contracts/dX6BiuAi6Ku#development-activities", "label": "Co Development and Option Agreement (Biotime Inc)", "score": 25.6078033447, "published": true}, {"hash": "5lO4mQ5mwqo", "uri": "/contracts/5lO4mQ5mwqo#development-activities", "label": "Stock Purchase Agreement (Biotime Inc)", "score": 23.6078033447, "published": true}], "size": 15, "snippet_links": [{"key": "committee-shall", "type": "definition", "offset": [17, 32]}, {"key": "comprised-of", "type": "definition", "offset": [36, 48]}, {"key": "certain-information", "type": "clause", "offset": [51, 70]}, {"key": "request-for-confidential-treatment", "type": "clause", "offset": [96, 130]}, {"key": "the-commission", "type": "clause", "offset": [180, 194]}, {"key": "electronic-means", "type": "clause", "offset": [336, 352]}, {"key": "steering-committee-members", "type": "clause", "offset": [375, 401]}, {"key": "functions-of-the-steering-committee", "type": "clause", "offset": [407, 442]}, {"key": "collaborative-research", "type": "definition", "offset": [467, 489]}, {"key": "joint-development-activities", "type": "definition", "offset": [494, 522]}, {"key": "monitoring-progress", "type": "clause", "offset": [534, 553]}, {"key": "the-development", "type": "clause", "offset": [560, 575]}, {"key": "engaging-in", "type": "definition", "offset": [592, 603]}, {"key": "of-information", "type": "definition", "offset": [614, 628]}, {"key": "planning-activities", "type": "clause", "offset": [639, 658]}, {"key": "task-forces", "type": "clause", "offset": [702, 713]}, {"key": "the-objective", "type": "clause", "offset": [793, 806]}, {"key": "each-party", "type": "clause", "offset": [818, 828]}, {"key": "relating-to", "type": "definition", "offset": [868, 879]}, {"key": "from-time-to-time", "type": "clause", "offset": [998, 1015]}, {"key": "during-the-term-of-this-agreement", "type": "clause", "offset": [1017, 1050]}, {"key": "to-amend", "type": "definition", "offset": [1052, 1060]}, {"key": "addition-of", "type": "clause", "offset": [1123, 1134]}, {"key": "statements-of-work", "type": "clause", "offset": [1135, 1153]}, {"key": "developed-intellectual-property", "type": "definition", "offset": [1179, 1210]}, {"key": "amendment-or", "type": "clause", "offset": [1232, 1244]}, {"key": "statement-of-work", "type": "definition", "offset": [1256, 1273]}, {"key": "approved-by", "type": "clause", "offset": [1297, 1308]}, {"key": "executed-by-the-parties", "type": "clause", "offset": [1396, 1419]}, {"key": "notwithstanding-the-foregoing", "type": "clause", "offset": [1487, 1516]}, {"key": "nothing-contained", "type": "definition", "offset": [1518, 1535]}, {"key": "either-party", "type": "definition", "offset": [1558, 1570]}, {"key": "section-21", "type": "clause", "offset": [1668, 1679]}, {"key": "activities-of-the", "type": "clause", "offset": [1693, 1710]}, {"key": "authority-to", "type": "definition", "offset": [1744, 1756]}, {"key": "the-principal-investigator", "type": "clause", "offset": [1850, 1876]}, {"key": "effective-date-of-this-agreement", "type": "definition", "offset": [1999, 2031]}, {"key": "the-parties-will", "type": "clause", "offset": [2033, 2049]}, {"key": "reasonable-efforts", "type": "clause", "offset": [2054, 2072]}, {"key": "in-accordance-with", "type": "clause", "offset": [2127, 2145]}, {"key": "terms-and-conditions-of-this-agreement", "type": "clause", "offset": [2150, 2188]}, {"key": "consistent-with", "type": "definition", "offset": [2331, 2346]}, {"key": "the-services", "type": "definition", "offset": [2403, 2415]}, {"key": "for-any-reason", "type": "clause", "offset": [2480, 2494]}, {"key": "both-parties", "type": "clause", "offset": [2782, 2794]}, {"key": "to-serve", "type": "definition", "offset": [2795, 2803]}, {"key": "substitute-principal", "type": "clause", "offset": [2870, 2890]}, {"key": "days-after", "type": "definition", "offset": [2947, 2957]}, {"key": "original-principal", "type": "definition", "offset": [2962, 2980]}, {"key": "services-under-this-agreement", "type": "clause", "offset": [3012, 3041]}, {"key": "an-additional", "type": "clause", "offset": [3063, 3076]}, {"key": "faculty-member", "type": "definition", "offset": [3178, 3192]}, {"key": "as-principal", "type": "clause", "offset": [3202, 3214]}, {"key": "during-the-extended", "type": "clause", "offset": [3304, 3323]}, {"key": "search-period", "type": "definition", "offset": [3324, 3337]}, {"key": "activities-under-this-agreement", "type": "clause", "offset": [3367, 3398]}, {"key": "replacement-principal", "type": "definition", "offset": [3416, 3437]}, {"key": "role-of-principal-investigator", "type": "clause", "offset": [3501, 3531]}, {"key": "in-writing", "type": "clause", "offset": [3560, 3570]}, {"key": "new-principal", "type": "clause", "offset": [3578, 3591]}, {"key": "to-act", "type": "definition", "offset": [3716, 3722]}, {"key": "time-periods", "type": "clause", "offset": [3861, 3873]}, {"key": "terminate-this-agreement", "type": "clause", "offset": [3902, 3926]}, {"key": "notice-thereof", "type": "clause", "offset": [3940, 3954]}, {"key": "other-party", "type": "definition", "offset": [3962, 3973]}, {"key": "article-11", "type": "definition", "offset": [4004, 4014]}, {"key": "termination-of-this-agreement", "type": "clause", "offset": [4016, 4045]}, {"key": "termination-for-breach", "type": "clause", "offset": [4086, 4108]}, {"key": "in-order-to", "type": "clause", "offset": [4110, 4121]}, {"key": "nature-of-the", "type": "clause", "offset": [4147, 4160]}, {"key": "the-parties-acknowledge", "type": "clause", "offset": [4185, 4208]}, {"key": "for-the-purpose-of", "type": "definition", "offset": [4359, 4377]}, {"key": "visiting-scientists", "type": "clause", "offset": [4426, 4445]}, {"key": "the-parties-agree-that", "type": "clause", "offset": [4449, 4471]}, {"key": "agreement-of-the-parties", "type": "clause", "offset": [4576, 4600]}, {"key": "the-parties-further-agree", "type": "clause", "offset": [4868, 4893]}, {"key": "attachment-c", "type": "clause", "offset": [5142, 5154]}, {"key": "prior-to", "type": "clause", "offset": [5156, 5164]}, {"key": "to-host", "type": "definition", "offset": [5272, 5279]}, {"key": "the-day", "type": "definition", "offset": [5389, 5396]}, {"key": "created-by", "type": "definition", "offset": [5459, 5469]}, {"key": "regulatory-landscape", "type": "clause", "offset": [5618, 5638]}, {"key": "genetic-testing", "type": "clause", "offset": [5678, 5693]}, {"key": "necessary-for", "type": "definition", "offset": [5747, 5760]}, {"key": "new-york-law", "type": "definition", "offset": [5807, 5819]}, {"key": "health-law", "type": "definition", "offset": [5841, 5851]}, {"key": "article-5", "type": "clause", "offset": [5859, 5868]}, {"key": "title-v", "type": "definition", "offset": [5870, 5877]}, {"key": "new-york-state", "type": "clause", "offset": [5927, 5941]}, {"key": "testing-of-samples", "type": "clause", "offset": [5946, 5964]}, {"key": "the-work", "type": "definition", "offset": [6038, 6046]}, {"key": "biological-samples", "type": "definition", "offset": [6145, 6163]}, {"key": "laboratory-facilities", "type": "clause", "offset": [6186, 6207]}, {"key": "patient-samples", "type": "clause", "offset": [6273, 6288]}, {"key": "applicable-law", "type": "definition", "offset": [6313, 6327]}, {"key": "in-good-faith", "type": "definition", "offset": [6466, 6479]}, {"key": "comply-with-the", "type": "clause", "offset": [6555, 6570]}, {"key": "sole-discretion", "type": "definition", "offset": [6695, 6710]}, {"key": "except-to-the-extent", "type": "clause", "offset": [6716, 6736]}, {"key": "agreed-to-by", "type": "definition", "offset": [6748, 6760]}, {"key": "good-faith-efforts", "type": "definition", "offset": [6792, 6810]}, {"key": "any-open", "type": "clause", "offset": [6852, 6860]}, {"key": "similar-software", "type": "clause", "offset": [6889, 6905]}, {"key": "general-public-license", "type": "clause", "offset": [6962, 6984]}, {"key": "agreement-or", "type": "definition", "offset": [7006, 7018]}, {"key": "a-party", "type": "clause", "offset": [7040, 7047]}, {"key": "object-code", "type": "definition", "offset": [7071, 7082]}, {"key": "to-third-parties", "type": "clause", "offset": [7093, 7109]}, {"key": "open-source-code", "type": "definition", "offset": [7126, 7142]}, {"key": "chief-technology-officer", "type": "clause", "offset": [7457, 7481]}], "snippet": "2.1 The Steering Committee shall be comprised of [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission]. The Steering Committee shall meet at least bi-monthly at mutually agreeable dates and places, including meeting by teleconference or other electronic means if agreed upon by all Steering Committee members. The functions of the Steering Committee shall be to oversee the collaborative research and joint development activities, including monitoring progress under the Development Activities, and engaging in exchanges of information and joint planning activities. The Steering Committee shall also appoint task forces or subcommittees, to the extent it may find it convenient or appropriate, with the objective of keeping each Party aware of relevant issues and decisions relating to the collaborative research and joint development under the Development Activities. The Steering Committee may propose from time to time, during the term of this Agreement, to amend or augment the Development Activities hereunder including the addition of statements of work to update or improve any Developed Intellectual Property hereunder. Each such amendment or additional statement of work shall be developed and approved by the Steering Committee, and, to the extent mutually agreeable to the Parties, shall be executed by the Parties and become a part of this Agreement as an exhibit attached hereto. Notwithstanding the foregoing, nothing contained herein shall obligate either Party to undertake additional or expanded activities. Notwithstanding the foregoing provisions of this Section 2.1, none of the activities of the Steering Committee shall give it authority to direct the Development Activities or otherwise to infringe upon the appropriate authority of the Principal Investigator in undertaking the Development Activities.\n2.2 Mount Sinai and LifeMap will commence the Development Activities after the Effective Date of this Agreement. The Parties will use reasonable efforts to undertake the Development Activities substantially in accordance with the terms and conditions of this Agreement. Notwithstanding the foregoing, LifeMap acknowledges that Mount Sinai will have the freedom to conduct the Development Activities in a manner consistent with Mount Sinai\u2019s educational and research missions.\n2.3 If the services of the Principal Investigator become unavailable to Mount Sinai for any reason, Mount Sinai shall notify LifeMap and shall undertake reasonable efforts to designate [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission] or another member of its faculty who is acceptable to both Parties to serve as the Principal Investigator of the Development Activities. If a substitute Principal Investigator has not been designated within ninety (90) days after the original Principal Investigator ceases his or her services under this Agreement, LifeMap may request an additional ninety (90) days, which extension must be granted, to identify an acceptable replacement Mount Sinai faculty member to serve as Principal Investigator and which replacement shall not be unreasonably objected to by Mount Sinai. During the extended search period, Mount Sinai may suspend its activities under this Agreement until a suitable replacement Principal Investigator has been identified and has agreed to take on the role of Principal Investigator, and Mount Sinai has agreed in writing to the new Principal Investigator. The Parties agree nothing contained herein shall obligate Mount Sinai to cause any Mount Sinai faculty member to act as Principal Investigator against such faculty member\u2019s wishes. If a mutually acceptable replacement cannot be found within the foregoing time periods, only then may either Party terminate this Agreement upon written notice thereof to the other Party, subject to the provisions of Article 11. Termination of this Agreement in such event shall not be considered a termination for breach. In order to \u2587\u2587\u2587\u2587\u2587\u2587 the collaborative nature of the Development Activities, the Parties acknowledge that LifeMap will request that Mount Sinai host, during the term of this Agreement, LifeMap employees or contractors in Mount Sinai facilities solely for the purpose of conducting the Development Activities (\u201cLifeMap Visiting Scientists\u201d). The Parties agree that hosting of any LifeMap Visiting Scientists in Mount Sinai facilities shall only be by the prior written agreement of the Parties and shall be limited to no more than [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission] LifeMap Visiting Scientists in cumulative total during the term of this Agreement. The Parties further agree that all such LifeMap Visiting Scientists shall be subject to Mount Sinai\u2019s policies regarding facility entrance and usage and that all said LifeMap Visiting Scientists shall be required to sign the Visiting Scientist Agreement, attached hereto as Attachment C, prior to being hosted at Mount Sinai. Notwithstanding the foregoing, nothing contained herein obligates Mount Sinai to host, or to continue to host, any LifeMap Visiting Scientists in its facilities. Procedures and details regarding the day-to-day collaborative environment and hosting shall be jointly created by Mount Sinai and LifeMap to the extent such procedures and details do not violate any Mount Sinai policies.\n2.4 The Parties acknowledge the evolving regulatory landscape surrounding direct-to-consumer patient genetic testing and that certain permit(s) and/or approval(s) may be necessary for such testing. By way of non-limiting example, New York law, including N.Y. Pub. Health Law \u00a7 574, Article 5, Title V, prohibits direct-to-consumer genetic testing in New York State and testing of samples obtained in New York State. As such, nothing contained herein, including the work outlined in the Development Activities, obligates Mount Sinai to sequence direct consumer patient biological samples in its New York State laboratory facilities or otherwise provide genetic testing for such direct-to-consumer patient samples in contravention of any applicable law. Should LifeMap desire Mount Sinai to sequence patient biological samples or otherwise provide genetic testing, the Parties will discuss, in good faith, potential avenues for Mount Sinai\u2019s participation in such activities that comply with the letter and spirit of applicable law, should Mount Sinai be agreeable to such participation, which agreement shall be at its sole discretion.\n2.5 Except to the extent reasonably agreed to by LifeMap, Mount Sinai shall use good faith efforts to avoid utilizing in the LMN Engine (i) any open source, free, community, or similar software, including any libraries or software licensed under the General Public License or any other license agreement or arrangement obliging a Party to make Source Code or object code available to third parties (collectively, \u201cOpen Source Code\u201d) or (ii) any code that requires the use of any Open Source Code in order to function in its intended fashion. Should Mount Sinai reasonably believe it needs to utilize such Open Source Code in the LMN Engine, it shall discuss in good faith with LifeMap such need and follow the processes specified by the LifeMap Chief Technology Officer, or other LifeMap officer, as appointed by the LifeMap Chief Technology Officer, prior to incorporating any such Open Source Code in the LMN Engine.", "hash": "e0ee4f3991c17444232b759bb40453bd", "id": 3}, {"samples": [{"hash": "l5unatGKA6d", "uri": "/contracts/l5unatGKA6d#development-activities", "label": "Production Sharing Agreement", "score": 25.4736480713, "published": true}, {"hash": "2Gd2ddtWiwe", "uri": "/contracts/2Gd2ddtWiwe#development-activities", "label": "Production Sharing Agreement", "score": 25.3189601898, "published": true}, {"hash": "j6obn0uSCN2", "uri": "/contracts/j6obn0uSCN2#development-activities", "label": "Production Sharing Agreement", "score": 25.3175907135, "published": true}], "size": 16, "snippet_links": [{"key": "the-development", "type": "clause", "offset": [0, 15]}], "snippet": "The Development activities referred to in item \u201cb\u201d of paragraph 3.1 include:", "hash": "2dc8a967723180f16369be56c8b2260c", "id": 2}, {"samples": [{"hash": "W8LYuUGA2v", "uri": "/contracts/W8LYuUGA2v#development-activities", "label": "Production Sharing Agreement", "score": 27.1436691284, "published": true}, {"hash": "3ublqI3GZHM", "uri": "/contracts/3ublqI3GZHM#development-activities", "label": "Production Sharing Agreement", "score": 23.3189601898, "published": true}, {"hash": "ln2DT8f3x2y", "uri": "/contracts/ln2DT8f3x2y#development-activities", "label": "Production Sharing Agreement", "score": 23.3175907135, "published": true}], "size": 17, "snippet_links": [{"key": "the-development", "type": "clause", "offset": [0, 15]}, {"key": "production-facilities", "type": "definition", "offset": [123, 144]}, {"key": "completion-of-the", "type": "clause", "offset": [159, 176]}, {"key": "installation-of-equipment", "type": "clause", "offset": [212, 237]}, {"key": "transfer-of", "type": "definition", "offset": [302, 313]}, {"key": "the-installation", "type": "clause", "offset": [327, 343]}, {"key": "not-limited", "type": "clause", "offset": [385, 396]}, {"key": "offshore-platforms", "type": "definition", "offset": [401, 419]}, {"key": "gas-treatment", "type": "definition", "offset": [440, 453]}, {"key": "equipment-and-facilities", "type": "definition", "offset": [462, 486]}, {"key": "measurement-of", "type": "clause", "offset": [491, 505]}, {"key": "wellhead-equipment", "type": "clause", "offset": [532, 550]}, {"key": "flow-lines", "type": "definition", "offset": [570, 580]}, {"key": "and-other-facilities", "type": "clause", "offset": [589, 609]}, {"key": "oil-and-gas-pipelines", "type": "clause", "offset": [658, 679]}, {"key": "pumping-stations", "type": "clause", "offset": [739, 755]}], "snippet": "The Development activities referred to in item \u201cb\u201d of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection \u2587\u2587\u2587\u2587\u2587; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item \u201cc\u201d includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.", "hash": "ea6b22588b6b9a64895bb7232d5e3f5d", "id": 1}, {"samples": [{"hash": "cNeEjE30FXy", "uri": "/contracts/cNeEjE30FXy#development-activities", "label": "License Agreement (BridgeBio Pharma, Inc.)", "score": 30.8507862091, "published": true}, {"hash": "adetwWK3Xuv", "uri": "/contracts/adetwWK3Xuv#development-activities", "label": "License Agreement (Eidos Therapeutics, Inc.)", "score": 30.8288841248, "published": true}], "size": 8, "snippet_links": [{"key": "right-and-responsibility", "type": "clause", "offset": [32, 56]}, {"key": "with-respect-to", "type": "clause", "offset": [91, 106]}, {"key": "licensed-compound", "type": "definition", "offset": [111, 128]}, {"key": "licensed-products", "type": "definition", "offset": [137, 154]}, {"key": "in-the-field", "type": "clause", "offset": [155, 167]}, {"key": "in-the-territory", "type": "clause", "offset": [168, 184]}, {"key": "sole-discretion", "type": "definition", "offset": [192, 207]}, {"key": "necessary-for", "type": "definition", "offset": [219, 232]}, {"key": "additional-clinical-trial", "type": "definition", "offset": [322, 347]}, {"key": "in-accordance-with", "type": "clause", "offset": [383, 401]}, {"key": "discretion-and-control", "type": "clause", "offset": [522, 544]}, {"key": "development-of-the", "type": "clause", "offset": [554, 572]}, {"key": "for-the-purpose-of", "type": "definition", "offset": [612, 630]}, {"key": "regulatory-approval", "type": "definition", "offset": [657, 676]}, {"key": "row-territory", "type": "definition", "offset": [749, 762]}, {"key": "notwithstanding-the-foregoing", "type": "clause", "offset": [764, 793]}, {"key": "use-commercially-reasonable-efforts", "type": "clause", "offset": [807, 842]}, {"key": "complete-the", "type": "clause", "offset": [866, 878]}, {"key": "the-final", "type": "clause", "offset": [951, 960]}, {"key": "completion-of-the", "type": "clause", "offset": [1017, 1034]}, {"key": "clinical-study-report", "type": "clause", "offset": [1041, 1062]}, {"key": "results-of-the", "type": "clause", "offset": [1181, 1195]}, {"key": "in-addition", "type": "clause", "offset": [1261, 1272]}, {"key": "in-good-faith", "type": "definition", "offset": [1295, 1308]}, {"key": "the-design", "type": "clause", "offset": [1449, 1459]}, {"key": "protocol-amendments", "type": "clause", "offset": [1478, 1497]}, {"key": "without-limiting-the-foregoing", "type": "clause", "offset": [1499, 1529]}, {"key": "right-to", "type": "definition", "offset": [1554, 1562]}, {"key": "at-any-time", "type": "clause", "offset": [1640, 1651]}, {"key": "written-consent", "type": "definition", "offset": [1675, 1690]}, {"key": "subject-to", "type": "clause", "offset": [1779, 1789]}, {"key": "pursuant-to", "type": "definition", "offset": [1945, 1956]}, {"key": "notice-thereof", "type": "clause", "offset": [2008, 2022]}, {"key": "receipt-of", "type": "clause", "offset": [2112, 2122]}, {"key": "in-writing", "type": "clause", "offset": [2163, 2173]}, {"key": "agrees-to", "type": "clause", "offset": [2188, 2197]}, {"key": "an-additional", "type": "clause", "offset": [2262, 2275]}, {"key": "written-request", "type": "definition", "offset": [2440, 2455]}, {"key": "the-parties-shall", "type": "clause", "offset": [2463, 2480]}, {"key": "by-mutual-agreement", "type": "definition", "offset": [2488, 2507]}, {"key": "relating-to", "type": "definition", "offset": [2520, 2531]}, {"key": "conduct-of-the", "type": "clause", "offset": [2536, 2550]}], "snippet": "(a) Alexion shall have the sole right and responsibility to conduct Development activities with respect to the Licensed Compound and the Licensed Products in the Field in the Territory in its sole discretion, except as necessary for Eidos to conduct the ATTRibute-CM Clinical Trial, the ATTRibute-PN Clinical Trial or any Additional Clinical Trial in the Territory following a [***] in accordance with Section 4.2(b).\n(b) Except as otherwise expressly set forth herein, Eidos shall have the sole right, and will have sole discretion and control over the Development of the Licensed Compound and Licensed Product for the purpose of obtaining and maintaining Regulatory Approval for the Commercialization of such Licensed Products in the Field in the ROW Territory. Notwithstanding the foregoing, Eidos shall use Commercially Reasonable Efforts to manage, conduct and complete the ATTRibute-CM Clinical Trial and the ATTRibute-PN Clinical Trial through the final dosing of the final subject in such Clinical Trials and completion of the final clinical study report for such Clinical Trials. Eidos shall keep Alexion reasonably informed, on at least [***] basis, as to the status and results of the ATTRibute-CM Clinical Trial and the ATTRibute-PN Clinical Trial. In addition, Eidos shall consider in good faith any comments provided by Alexion with respect to the ATTRibute-CM Clinical Trial and the ATTRibute-PN Clinical Trial, including comments on the design and any potential protocol amendments. Without limiting the foregoing, Alexion shall have the right to (i) require, in its sole discretion, that Eidos [***], or request such [***] at any time thereafter with Eidos\u2019 written consent, not to be unreasonably withheld, conditioned or delayed, (ii) request that Eidos [***] subject to Eidos\u2019 written consent, not to be unreasonably withheld, conditioned or delayed; and (iii) require that Eidos [***]. If Alexion wishes to initiate a [***] pursuant to this Section 4.2(b), Alexion shall provide written notice thereof to Eidos. If Alexion is requesting (rather than requiring) [***], within [***] of Eidos\u2019 receipt of such notice, Eidos shall inform Alexion in writing whether Eidos agrees to the requested [***]. Additionally, if Eidos intends to initiate an additional Clinical Trial in the ROW Territory (each such Clinical Trial, an \u201cAdditional Trial\u201d), Eidos shall provide prompt written notice thereof to Alexion. Upon Alexion\u2019s written request [***]. The Parties shall decide by mutual agreement all matters relating to the conduct of the ATTRibute-CM Clinical Trial, ATTRibute-PN Clinical Trial and the Additional Trial in the Territory, including the choice of Clinical Trial sites, and the Parties shall conduct the ATTRibute-CM Clinical Trial, ATTRibute-PN Clinical Trial or the Additional Trial, as applicable, in the Territory in accordance with such decisions.", "hash": "db33eb3c6ed14e1c5a0a8f020a4b065e", "id": 6}, {"samples": [{"hash": "hNUGyID97Mw", "uri": "/contracts/hNUGyID97Mw#development-activities", "label": "Revolving Credit Agreement (Kilroy Realty Corp)", "score": 18.0, "published": true}, {"hash": "3PEqG05b2mq", "uri": "/contracts/3PEqG05b2mq#development-activities", "label": "Revolving Credit Agreement (Kilroy Realty Corp)", "score": 18.0, "published": true}], "size": 8, "snippet_links": [{"key": "the-borrower-shall", "type": "clause", "offset": [0, 18]}, {"key": "for-development", "type": "clause", "offset": [90, 105]}, {"key": "in-connection-with", "type": "clause", "offset": [106, 124]}, {"key": "casualty-or-condemnation", "type": "clause", "offset": [187, 211]}, {"key": "existing-improvements", "type": "clause", "offset": [215, 236]}, {"key": "real-property-assets", "type": "definition", "offset": [240, 260]}, {"key": "notwithstanding-the-foregoing", "type": "clause", "offset": [262, 291]}, {"key": "other-development-activities", "type": "clause", "offset": [324, 352]}, {"key": "construction-completion", "type": "definition", "offset": [368, 391]}, {"key": "provided-that", "type": "definition", "offset": [397, 410]}, {"key": "in-no-event-shall", "type": "clause", "offset": [411, 428]}, {"key": "the-value", "type": "clause", "offset": [429, 438]}, {"key": "in-accordance-with", "type": "clause", "offset": [451, 469]}, {"key": "the-definition-of", "type": "clause", "offset": [470, 487]}, {"key": "combined-asset-value", "type": "definition", "offset": [488, 508]}, {"key": "the-real-property", "type": "clause", "offset": [513, 530]}, {"key": "type-of-development", "type": "clause", "offset": [555, 574]}, {"key": "of-the-borrower", "type": "clause", "offset": [603, 618]}], "snippet": "The Borrower shall not engage ---------------------- in any development activities except for development in connection with the expansion and/or repositioning or restoration following a casualty or condemnation of existing improvements on Real Property Assets. Notwithstanding the foregoing, the Borrower may engage in all other development activities where there is construction completion risk provided that in no event shall the value (determined in accordance with the definition of Combined Asset Value) of the Real Property Assets under such other type of development exceed twenty percent (20%) of the Borrower's Combined Asset Value.", "hash": "6c084f20b8b8ae66b63eb9601f2d7114", "id": 7}, {"samples": [{"hash": "4rMuIvIgtdq", "uri": "/contracts/4rMuIvIgtdq#development-activities", "label": "Intergovernmental Agreement", "score": 33.0180587769, "published": true}, {"hash": "gA4HcFZ8B3m", "uri": "/contracts/gA4HcFZ8B3m#development-activities", "label": "Intergovernmental Agreement", "score": 32.8291816711, "published": true}, {"hash": "7spTgIb79QG", "uri": "/contracts/7spTgIb79QG#development-activities", "label": "Intergovernmental Agreement", "score": 32.7325210571, "published": true}], "size": 6, "snippet_links": [{"key": "in-consideration-of-the", "type": "clause", "offset": [0, 23]}, {"key": "by-the-city", "type": "clause", "offset": [57, 68]}, {"key": "other-promises", "type": "clause", "offset": [99, 113]}, {"key": "in-the-city", "type": "definition", "offset": [239, 250]}, {"key": "cooperation-with-the", "type": "clause", "offset": [272, 292]}, {"key": "other-agreements", "type": "definition", "offset": [374, 390]}, {"key": "the-provisions", "type": "clause", "offset": [507, 521]}, {"key": "the-purposes-of-this-agreement", "type": "clause", "offset": [537, 567]}, {"key": "monetary-obligation", "type": "clause", "offset": [658, 677]}, {"key": "approved-by", "type": "clause", "offset": [750, 761]}, {"key": "prior-to", "type": "clause", "offset": [771, 779]}, {"key": "entered-into", "type": "clause", "offset": [786, 798]}, {"key": "from-time-to-time", "type": "clause", "offset": [814, 831]}, {"key": "acquire-property", "type": "clause", "offset": [845, 861]}, {"key": "development-purposes", "type": "definition", "offset": [925, 945]}, {"key": "dispose-of", "type": "definition", "offset": [958, 968]}, {"key": "private-parties", "type": "clause", "offset": [1038, 1053]}, {"key": "implementation-activities", "type": "definition", "offset": [1097, 1122]}, {"key": "deemed-necessary", "type": "definition", "offset": [1130, 1146]}, {"key": "predevelopment-activities", "type": "definition", "offset": [1183, 1208]}, {"key": "site-analysis", "type": "clause", "offset": [1217, 1230]}, {"key": "environmental-analysis", "type": "clause", "offset": [1232, 1254]}, {"key": "development-planning", "type": "clause", "offset": [1256, 1276]}, {"key": "market-analysis", "type": "definition", "offset": [1278, 1293]}, {"key": "feasibility-studies", "type": "definition", "offset": [1305, 1324]}, {"key": "preliminary-design", "type": "definition", "offset": [1326, 1344]}, {"key": "zoning-compliance", "type": "definition", "offset": [1346, 1363]}, {"key": "redevelopment-plans", "type": "definition", "offset": [1422, 1441]}, {"key": "to-ensure", "type": "clause", "offset": [1442, 1451]}, {"key": "overall-goals", "type": "clause", "offset": [1480, 1493]}, {"key": "short-term", "type": "clause", "offset": [1498, 1508]}], "snippet": "In consideration of the payments and appropriations made by the City under this Agreement, and the other promises and commitments made hereunder, the URA agrees that it shall undertake the following activities whenever and wherever needed in the City, in coordination and cooperation with the City:\n1. The URA may enter into and execute any contracts, leases, mortgages, or other agreements, including agreements with bondholders or lenders, determined by the URA to be necessary or convenient to implement the provisions and effectuate the purposes of this Agreement. All such contracts, leases, mortgages, or other agreements which impose upon the URA any monetary obligation which cannot be satisfied without money from the City\u2019s budget shall be approved by the City prior to being entered into by the URA.\n2. From time to time, the URA may acquire property, real or personal, or interests therein, for redevelopment and development purposes, and use or dispose of such property or interests, either through the City or directly with private parties.\n3. The URA may conduct other planning and implementation activities as are deemed necessary and prudent, including planning and predevelopment activities such as site analysis, environmental analysis, development planning, market analysis, financial feasibility studies, preliminary design, zoning compliance, facilities inspections, and overall analysis of proposed redevelopment plans to ensure consistency with the City's overall goals and short term and long-range plans.", "hash": "de00906cc56c0cd114b4dc3260da27e4", "id": 8}, {"samples": [{"hash": "9GRY3JUkmTM", "uri": "/contracts/9GRY3JUkmTM#development-activities", "label": "License and Collaboration Agreement (Seagen Inc.)", "score": 31.8186168671, "published": true}, {"hash": "klsoJvkwYek", "uri": "/contracts/klsoJvkwYek#development-activities", "label": "License and Collaboration Agreement (Genmab a/S)", "score": 30.4017791748, "published": true}, {"hash": "9IyrDdoXRnW", "uri": "/contracts/9IyrDdoXRnW#development-activities", "label": "License and Collaboration Agreement (Genmab a/S)", "score": 30.2484607697, "published": true}], "size": 5, "snippet_links": [{"key": "each-party", "type": "clause", "offset": [0, 10]}, {"key": "efforts-to-perform", "type": "clause", "offset": [45, 63]}, {"key": "with-respect-to", "type": "clause", "offset": [80, 95]}, {"key": "the-development", "type": "clause", "offset": [96, 111]}, {"key": "collaboration-product", "type": "clause", "offset": [120, 141]}, {"key": "in-accordance-with", "type": "clause", "offset": [142, 160]}, {"key": "joint-development-plan", "type": "clause", "offset": [172, 194]}, {"key": "joint-budget", "type": "definition", "offset": [199, 211]}, {"key": "all-applicable-laws", "type": "definition", "offset": [274, 293]}, {"key": "personnel-and-facilities", "type": "clause", "offset": [394, 418]}, {"key": "obligations-under-the", "type": "clause", "offset": [446, 467]}, {"key": "relating-to", "type": "definition", "offset": [566, 577]}, {"key": "development-of-a", "type": "clause", "offset": [582, 598]}, {"key": "in-good-faith", "type": "definition", "offset": [639, 652]}, {"key": "the-parties-acknowledge-and-agree-that", "type": "clause", "offset": [686, 724]}, {"key": "neither-party", "type": "clause", "offset": [725, 738]}, {"key": "development-tasks", "type": "definition", "offset": [769, 786]}], "snippet": "Each Party shall use Commercially Reasonable Efforts to perform its obligations with respect to the Development of each Collaboration Product in accordance with the latest Joint Development Plan and Joint Budget and all such activities shall be conducted in accordance with all Applicable Laws, including as applicable, GCPs, GLPs and GMPs. As part of such efforts, each Party shall commit the personnel and facilities necessary to carry out its obligations under the latest Joint Development Plan. Neither SGI nor Genmab shall be required to undertake any activity relating to the Development of a Collaboration Product that it believes, in good faith, may violate any Applicable Law. The Parties acknowledge and agree that neither Party guarantees the success of the Development tasks undertaken hereunder.", "hash": "13a6db93d1b10603cea6973ddf903327", "id": 9}, {"samples": [{"hash": "jUnm9BYV8PD", "uri": "/contracts/jUnm9BYV8PD#development-activities", "label": "License, Development and Commercialization Agreement (Zura Bio LTD)", "score": 34.6071166992, "published": true}, {"hash": "2XLyVNS4cra", "uri": "/contracts/2XLyVNS4cra#development-activities", "label": "License, Development and Commercialization Agreement (JATT Acquisition Corp)", "score": 34.1279945374, "published": true}, {"hash": "5Of9jFuelGL", "uri": "/contracts/5Of9jFuelGL#development-activities", "label": "License, Development and Commercialization Agreement (JATT Acquisition Corp)", "score": 34.0212173462, "published": true}], "size": 5, "snippet_links": [{"key": "licensee-shall", "type": "clause", "offset": [0, 14]}, {"key": "the-development", "type": "clause", "offset": [31, 46]}, {"key": "the-product", "type": "clause", "offset": [62, 73]}, {"key": "development-plan", "type": "definition", "offset": [95, 111]}, {"key": "in-accordance-with", "type": "clause", "offset": [112, 130]}, {"key": "time-frames", "type": "clause", "offset": [135, 146]}, {"key": "approval-of", "type": "definition", "offset": [239, 250]}, {"key": "in-the-territory", "type": "clause", "offset": [275, 291]}], "snippet": "Licensee shall [***] carry out the Development Activities for the Product under the applicable Development Plan in accordance with the time frames set forth therein and in a manner designed to achieve successful Development and Regulatory Approval of the Compound or Product in the Territory.", "hash": "1f84a19529d868e56dc63d278eb49579", "id": 10}], "next_curs": "Cl8SWWoVc35sYXdpbnNpZGVyY29udHJhY3RzcjsLEhZDbGF1c2VTbmlwcGV0R3JvdXBfdjU2Ih9kZXZlbG9wbWVudC1hY3Rpdml0aWVzIzAwMDAwMDBhDKIBAmVuGAAgAA==", "clause": {"title": "Development Activities", "size": 677, "parents": [["development", "Development"], ["objectives-under-the-development-plan", "Objectives Under the Development Plan"], ["affirmative-and-negative-covenants", "AFFIRMATIVE AND NEGATIVE COVENANTS"], ["development-and-regulatory-activities", "Development and Regulatory Activities"], ["development-program", "Development Program"]], "children": [["general", "General"], ["reports", "Reports"], ["development-costs", "Development Costs"], ["regulatory-matters", "Regulatory Matters"], ["clinical-trials", "Clinical Trials"]], "id": "development-activities", "related": [["development-program", "Development Program", "Development Program"], ["development-and-commercialization", "Development and Commercialization", "Development and Commercialization"], ["collaboration-activities", "Collaboration activities", "Collaboration activities"], ["development-plan", "Development Plan", "Development Plan"], ["development-work", "Development Work", "Development Work"]], "related_snippets": [], "updated": "2026-03-28T04:49:54+00:00", "also_ask": ["What key milestones and deliverables should be explicitly defined in the Development Activities clause?", "How can the clause allocate risks for delays, cost overruns, or failure to meet specifications?", "What negotiation leverage points exist regarding approval rights and change management?", "How does this clause compare to industry standards or similar agreements in terms of developer obligations?", "What are the most common enforceability challenges for Development Activities clauses in court?"], "drafting_tip": "Specify permitted development activities to prevent unauthorized actions, define approval processes to ensure oversight, and set timelines to promote project efficiency.", "explanation": "The 'Development Activities' clause defines the scope and parameters of work related to the creation, design, or improvement of a product, service, or project. It typically outlines the specific tasks, milestones, and responsibilities assigned to each party during the development phase, such as timelines for deliverables, quality standards, and reporting requirements. By clearly delineating these activities, the clause ensures that both parties have a mutual understanding of expectations and obligations, thereby reducing the risk of misunderstandings or disputes during the development process."}, "json": true, "cursor": ""}}